Sipironolactone prevents the heart againts anthracycline cardiotoxicity

Abstract

Aim: The most important adverse event of anthracyclines is cardiotoxicity and can limit the use of them. Spironolactone is an aldosterone antagonist and has antifibrotic and antioxidant effects. In the present study, we aimed to investigate the effects of spironolactone in the prevention of the cardiotoxic effects of the anthracycline. Materials and methods: A total of 83 female patients who diagnosed with breast cancer and planned anthracycline including chemotherapy regimen were enrolled in to the study. Study population were randomized as spironolactone and control group. Twenty five mg/day spironolactone was administrated to the patients in spironolactone group. Results: LVEF decreased from 67.0±6.1 to 65.7±7.4 (p=0.094) in the spironolactone group, while from 67.7±6.3 to 53.6±6.8 in control group (p<0.001). Diastolic functional class was prevented in spironolactone group (p=0.247). In the control group, however, diastolic functional class was deteriorated (p<0.001). Mitral inflow E wave/lateral wall e' wave ratio which is one of the most important sign of the diastolic functions was significantly increased in the control group while prevented in the spironolactone group. ![Figure][1] Figure 1 Conclusions: Prophylactic administration of spironolactone 25 mg/day prevents the left ventricular systolic and diastolic functions in patients who administrated anthracyclines. [1]: pending:yes